FDA Lifts Hold on Aastrom Stem Cell Clinical Trial

Dont be the last to know about court actions and bills that will affect your operations.

Subscribe to Washington Drug Letter (WDL) and receive concise coverage of the FDAs and other regulators actions, congressional legislation and hearings, federal and state court decisions, and industry moves to influence government policies and procedures.

Each issue provides:

Imagine receiving this crucial coverage 50 times a year.

PLUS: in every issue, you get links to additional key documents that support WDLs articles, such as FDA letters, guidances, warning letters and 483s, rules, full texts of proposed legislation, GAO reports and more. Other features include:

BONUS: Place your order NOW and save $200 off the regular one-year price of $1,347 - plus receive a FREE copy of our webinar CD, REMS 2014: Prepare for New Clarifying Guidances and Assessment Requirements - regularly $347, FREE with your paid subscription.

Theres absolutely no risk to you. You get our 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Washington Drug Letter, you may cancel your subscription and receive a full refund. No questions asked.

So, why wait? Become a subscriber to Washington Drug Letter today. It couldnt be easier.

Weekly, 50 issues/year, Electronic Delivery

Read the original post:
FDA Lifts Hold on Aastrom Stem Cell Clinical Trial